


AMENDMENTS TO THE CLAIMS

1. **(Previously presented)** An indoline compound represented by the formula (I)



wherein

R^1 and R^3

are the same or different and each is hydrogen atom, lower alkyl group or lower alkoxy group,

R^2 is $-NHSO_2R^6$ [R^6 is alkyl group, aryl group or $-NHR^7$ (R^7 is hydrogen atom, $-COR^{13}$ (R^{13} is hydrogen atom or lower alkyl group) or lower alkoxycarbonyl group)], $-NHCONH_2$ or lower alkyl group substituted by $-NHSO_2R^6$ [R^6 is alkyl group, aryl group or $-NHR^7$ (R^7 is hydrogen atom, $-COR^{13}$ (R^{13} is hydrogen atom or lower alkyl group) or lower alkoxycarbonyl group)],

R^4 is alkyl group optionally substituted by hydroxy group, $-COR^{13}$ (R^{13} is hydrogen atom or lower alkyl group), lower alkenyl group, lower alkoxy lower alkyl group, lower alkylthio lower alkyl group, cycloalkyl group or cycloalkylalkyl group,

R^5 is alkyl group, cycloalkyl group or aryl group,

R^{12} is hydrogen atom, lower alkyl group, lower alkoxy lower alkyl group or lower alkylthio lower alkyl group,

or a pharmaceutically acceptable salt thereof.

2. **(Previously presented)** The indoline compound of claim 1, wherein, in the formula (I),

R¹ and R³ are the same or different and each is hydrogen atom, lower alkyl group or lower alkoxy group,

R² is -NHSO₂R⁶ [R⁶ is alkyl group, aryl group or -NHR⁷ (R⁷ is hydrogen atom, -COR¹³ (R¹³ is hydrogen atom or lower alkyl group) or lower alkoxycarbonyl group)], -NHCONH₂ or lower alkyl group substituted by -NHSO₂R⁶ [R⁶ is alkyl group, aryl group or -NHR⁷ (R⁷ is hydrogen atom, -COR¹³ (R¹³ is hydrogen atom or lower alkyl group) or lower alkoxycarbonyl group)],

R⁴ is alkyl group, cycloalkyl group or cycloalkylalkyl group,

R⁵ is alkyl group, cycloalkyl group or aryl group, and

R¹² is hydrogen atom,

or a pharmaceutically acceptable salt thereof.

3. **(Previously presented)** The indoline compound of claim 1, wherein, in the formula (I), R² is -NHSO₂R⁶ [R⁶ is alkyl group or -NHR⁷ (R⁷ is hydrogen atom)],

R⁴ is alkyl group optionally substituted by hydroxy group, -COR¹³ (R¹³ is hydrogen atom or lower alkyl group), lower alkenyl group, lower alkoxy lower alkyl group or lower alkylthio lower alkyl group,

R⁵ is alkyl group, and

R¹² is hydrogen atom, lower alkyl group, lower alkoxy lower alkyl group or lower alkylthio lower alkyl group,

or a pharmaceutically acceptable salt thereof.

4. **(Previously presented)** The indoline compound of claim 2, wherein, in the formula (I), R² is -NHSO₂R⁶ [R⁶ is alkyl group or -NHR⁷ (R⁷ is hydrogen atom)] or -NHCONH₂, or a pharmaceutically acceptable salt thereof.

5. **(Previously presented)** The indoline compound of claim 2, wherein, in the formula (I),

R^2 or $-NHCOR^5$ is bonded to the 5-position of indoline, and the other is bonded to the 7-position of indoline, or a pharmaceutically acceptable salt thereof.

6. **(Previously presented)** The indoline compound of claim 3, wherein, in the formula (I), R^2 is bonded to the 5-position of indoline, and $-NHCOR^5$ is bonded to the 7-position of indoline, or a pharmaceutically acceptable salt thereof.

7. **(Previously presented)** The indoline compound of claim 4, wherein, in the formula (I), R^2 is bonded to the 5-position of indoline, and $-NHCOR^5$ is bonded to the 7-position of indoline, or a pharmaceutically acceptable salt thereof.

8. **(Previously presented)** The indoline compound of claim 6, wherein, in the formula (I), R^4 is lower alkoxy lower alkyl group or lower alkylthio lower alkyl group, and R^{12} is hydrogen atom or lower alkyl group, or a pharmaceutically acceptable salt thereof.

9. **(Previously presented)** The indoline compound of claim 8, wherein, in the formula (I), R^1 and R^3 are lower alkyl groups, or a pharmaceutically acceptable salt thereof.

10. **(Previously presented)** The indoline compound of claim 6, wherein, in the formula (I), R^{12} is bonded to the 2-position of indoline, or a pharmaceutically acceptable salt thereof.

11. **(Previously presented)** The indoline compound of claim 10, wherein, in the formula (I), R^4 is alkyl group, R^{12} is lower alkoxy lower alkyl group or lower alkylthio lower alkyl group, or a pharmaceutically acceptable salt thereof.

12. **(Previously presented)** The indoline compound of claim 11, wherein, in the formula (I), R^1 and R^3 are lower alkyl groups, or a pharmaceutically acceptable salt thereof.

13. **(Previously presented)** The indoline compound of claim 7, wherein, in the formula (I), R^1 and R^3 are lower alkyl groups, and R^5 is alkyl group, or a pharmaceutically acceptable salt thereof.

14. **(Previously presented)** The indoline compound of claim 13, wherein, in the formula (I), R^2 is $-NHSO_2R^6$ (R^6 is alkyl group), or a pharmaceutically acceptable salt thereof.

15. **(Previously presented)** The indoline compound of claim 13, wherein, in the formula (I), R^2 is $-NHSO_2R^6$ [R^6 is $-NHR^7$ (R^7 is hydrogen atom)], or a pharmaceutically acceptable salt thereof.

16. **(Previously presented)** The indoline compound of claim 13, wherein, in the formula (I), R^2 is $-NHCONH_2$, or a pharmaceutically acceptable salt thereof.

17. **(Previously presented)** The indoline compound of claim 2, wherein the compound of the formula (I) is any of the following (1)-(5), or a pharmaceutically acceptable salt thereof:

- (1) N-(5-methanesulfonylamino-4,6-dimethyl-1-propylindolin-7-yl)-2,2-dimethylpropanamide,
- (2) N-[5-methanesulfonylamino-4,6-dimethyl-1-(2-methylpropyl)indolin-7-yl]-2,2-dimethylpropanamide,
- (3) N-(1-butyl-5-methanesulfonylamino-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
- (4) N-[5-methanesulfonylamino-4,6-dimethyl-1-(3-methylbutyl)indolin-7-yl]-2,2-dimethylpropanamide,
- (5) N-(5-methanesulfonylamino-4,6-dimethyl-1-pentylindolin-7-yl)-2,2-dimethylpropanamide.

18. **(Previously presented)** The indoline compound of claim 2, wherein the compound of the formula (I) is the following (1) or (2), or a pharmaceutically acceptable salt thereof:

- (1) N-(5-methanesulfonylamino-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide,
- (2) N-(1-hexyl-5-methanesulfonylamino-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

19. (Previously presented) The indoline compound of claim 2, wherein the compound of the formula (I) is the following (1) or (2), or a pharmaceutically acceptable salt thereof:

- (1) N-(1-ethyl-5-methanesulfonylamino-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
- (2) N-(5-methanesulfonylamino-1,4,6-trimethylindolin-7-yl)-2,2-dimethylpropanamide.

20. (Previously presented) The indoline compound of claim 2, wherein the compound of the formula (I) is any of the following (1)-(6), or a pharmaceutically acceptable salt thereof:

- (1) N-(4,6-dimethyl-1-octyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (2) N-(4,6-dimethyl-1-propyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (3) N-(4,6-dimethyl-1-pentyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (4) N-[4,6-dimethyl-1-(2-methylpropyl)-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide,
- (5) N-(1-butyl-4,6-dimethyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (6) N-[4,6-dimethyl-1-(3-methylbutyl)-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide.

21. (Currently amended) The indoline compound of claim 2, wherein the compound of the formula (I) is ~~any of the following (1)-(7), or a pharmaceutically acceptable salt thereof:~~

- ~~(1) N-(7-methanesulfonylamino-1,4,6-trimethylindolin-5-yl)-2,2-dimethylundecanamide, or a pharmaceutically acceptable salt thereof.~~
- ~~(2) N-(7-methanesulfonylamino-4,6-dimethylindolin-5-yl)-2,2-dimethylundecanamide,~~
- ~~(3) N-[7-(2-propanesulfonylamino)-4,6-dimethylindolin-5-yl]-2,2-dimethylundecanamide,~~
- ~~(4) N-[7-(2-propanesulfonylamino)-4,6-dimethylindolin-5-yl]-2,2-dimethyloctanamide,~~
- ~~(5) N-[4,6-dimethyl-7-(p-toluene)sulfonylaminoindolin-5-yl]-2,2-dimethylundecanamide,~~
- ~~(6) N-(4,6-dimethyl-7-sulfamoylaminoindolin-5-yl)-2,2-dimethylundecanamide,~~

~~(7) N-(4,6-dimethyl-7-ureidolindolin-5-yl)-2,2-dimethylundecanamide.—~~

22. (Currently amended) The indoline compound of claim 2, wherein the compound of the formula (I) is any of the following ~~(1)-(5)~~(1)-(4), or a pharmaceutically acceptable salt thereof:

~~(1) N-(4,6-dimethyl-5-nitro-1-octylindolin-7-yl)-2,2-dimethylpropanamide,—~~

~~(2)~~(1) N-(5-methanesulfonylaminoethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide,

~~(3)~~(2) N-(4,6-dimethyl-1-octyl-5-ureidolindolin-7-yl)-2,2-dimethylpropanamide,

~~(4)~~(3) N-[5-(N-acetylsulfamoylamino)-4,6-dimethyl-1-octylindolin-7-yl]-2,2-dimethylpropanamide,

~~(5)~~(4) N-[5-(N-methoxycarbonylsulfamoylamino)-4,6-dimethyl-1-octylindolin-7-yl]-2,2-dimethylpropanamide.

23. (Previously presented) The indoline compound of claim 9, wherein, in the formula (I), R^2 is $-NHSO_2R^6$ (R^6 is alkyl group), or a pharmaceutically acceptable salt thereof.

24. (Previously presented) The indoline compound of claim 9, wherein, in the formula (I), R^2 is $-NHSO_2R^6$ [R^6 is $-NHR^7$ (R^7 is hydrogen atom)], or a pharmaceutically acceptable salt thereof.

25. (Previously presented) The indoline compound of claim 2, wherein the compound of the formula (I) is any of the following (1)-(6), or a pharmaceutically acceptable salt thereof:

(1) N-(1-isopropyl-5-methanesulfonylamino-4,6-dimethylindoline 7-yl)-2,2-dimethylpropanamide,

(2) N-[1-(2,2-dimethylpropyl)-5-methanesulfonylamino-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide,

(3) N-(1-cyclobutylmethyl-5-methanesulfonylamino-4,6-dimethylindolin-7-yl)-2,2-

dimethylpropanamide,

(4) N-(1-cyclopentyl-5-methanesulfonylamino-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,

(5) N-(1-cyclopentyl-4,6-dimethyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,

(6) N-(1-cyclopropylmethyl-5-methanesulfonylamino-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.

26. (Previously presented) The indoline compound of claim 3, wherein the compound of the formula (I) is N-[5-methanesulfonylamino-4,6-dimethyl-1-(3-methyl-2-butenyl)indolin-7-yl]-2,2-dimethylpropanamide, or a pharmaceutically acceptable salt thereof.

27. (Previously presented) The indoline compound of claim 3, wherein the compound of the formula (I) any of the following (1)-(6), or a pharmaceutically acceptable salt thereof:

(1) N-[1-(2-ethoxyethyl)-4,6-dimethyl-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide,

(2) N-[1-(2-ethoxyethyl)-2,4,6-trimethyl-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide,

(3) N-[1-(2-methoxyethyl)-4,6-dimethyl-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide,

(4) N-[1-(2-methoxyethyl)-2,4,6-trimethyl-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide,

(5) N-[1-(2-ethylthioethyl)-4,6-dimethyl-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide hydrochloride,

(6) N-[4,6-dimethyl-1-(2-methylthioethyl)-5-sulfamoylaminoindolin-7-yl]-2,2-dimethylpropanamide hydrochloride.

28. (Previously presented) The indoline compound of claim 3, wherein the compound of the formula (I) is any of the following (1)-(4), or a pharmaceutically acceptable salt thereof:

- (1) N-(2-methoxymethyl-4,6-dimethyl-1-propyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (2) N-(2-ethoxymethyl-4,6-dimethyl-1-propyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (3) N-(2-methylthiomethyl-4,6-dimethyl-1-propyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide,
- (4) N-(2-ethylthiomethyl-4,6-dimethyl-1-propyl-5-sulfamoylaminoindolin-7-yl)-2,2-dimethylpropanamide.

29. (Previously presented) The indoline compound of claim 3, wherein the compound of the formula (I) is the following (1) or (2), or a pharmaceutically acceptable salt thereof:

- (1) N-[1-(2-ethoxyethyl)-5-methanesulfonylamino-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide,
- (2) N-[1-(2-methoxyethyl)-5-methanesulfonylamino-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide.

30. (Previously presented) A pharmaceutical composition comprising the indoline compound of claim 1, or a pharmaceutically acceptable salt thereof.

31. (Previously presented) An acyl-coenzyme A: cholesterol acyl transferase inhibitor comprising the indoline compound of claim 1, or a pharmaceutically acceptable salt thereof.

32. (Previously presented) A lipoperoxidation inhibitor comprising the indoline compound of claim 1, or a pharmaceutically acceptable salt thereof.

33. (Previously presented) The indoline compound of claim 12, wherein, in the formula (I), R^2 is $-NHSO_2R^6$ (R^6 is alkyl group), or a pharmaceutically acceptable salt thereof.

34. (Previously presented) The indoline compound of claim 12, wherein, in the formula (I), R^2 is $-NHSO_2R^6$ [R^6 is $-NHR^7$ (R^7 is hydrogen atom)], or a pharmaceutically acceptable salt thereof.